SPX3,998.84-72.86 -1.79%
DIA340.03-4.71 -1.37%
IXIC11,239.94-221.56 -1.93%

--BMO Capital Adjusts Price Target on ImmunoGen to $19 From $17, Maintains Outperform Rating

--BMO Capital Adjusts Price Target on ImmunoGen to $19 From $17, Maintains Outperform Rating

MT Newswires · 11/16/2022 04:40

Please log in to view news